Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AMG 701 + Lenalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMG 701||AMG-701|AMG701|BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody AMG 701||CD3 Antibody 20||AMG 701 is a bi-specific T-cell engager (BiTE) antibody that simultaneously binds to BCMA (TNFRSF17) and CD3, and activates cytotoxic T-lymphocytes against tumor cells expressing BCMA, potentially inducing death of BCMA expressing tumor cells (NCI Drug Dictionary).|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||AMG 701 + Lenalidomide||Preclinical||Actionable||In a preclinical study, AMG 701 and Revlimid (lenalidomide) combination treatment enhanced tumor growth inhibition and regression in a mouse model of multiple myeloma (Blood (2019) 134 (Supplement_1): 135).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|